ACUTE FLACCID PARALYSIS REGISTERED FOR THE PERIOD 2012-2020, IN STARA ZAGORA REGION

• Main Authors: I. Simeonova, Sv. Petrova, I. Mladenova
• Format: Article
• Language: English
• Published: Trakia University 2021-06-01
• Series: Trakia Journal of Sciences
• Subjects: acute flaccid paralysis; polio eradication; inactivated polio vaccine
• Online Access: http://tru.uni-sz.bg/tsj/Volume%2019,%202021,%20Number%202,%20Series%20Biomedical%20Sciences/7.pdf

Acute Flaccid Paralysis (AFP) is a clinical syndrome. There are many infectious and non-infectious causes of AFP. Poliomyelitis caused by the wild polio virus (the natural circulating strain of polio) is one of the causes of AFP. As a part of the worldwide campaign to eradicate polio, all countries do surveillance for polio by looking for clinical cases of AFP. The purpose of the study is to describe the cases of Acute Flaccid Paralysis, without Paresis Nervi facialis, in the Stara Zagora region for the period 2012-2020. Methods: A retrospective, descriptive analysis was performed on the parameters: diagnosis, seasonality, sex, residence, age, clinical data, and comorbidities, results of follow-up examinations, polio vaccine administration, and timeliness of studies. Results: There were 9 cases of AFP, without Paresis nervi facialis, registered and reported for the Stara Zagora region, for the period 2012 – 2020. The children in 3 years old were more affected- 4 patients. About the coverage with polio vaccine: 7 of the patients had 4 doses, 1- had 6 doses, 1 child had 5 doses, and + 1 zero dose. 100% of children are covered, according to their age, with IPV. Follow-up in 6 of the patients is without residual paresis and complications. Residual paresis was found in 1 of the cases. In 2 patients no control examination was performed due to migration. Conclusion: The correct epidemiological diagnosis is the way to timely and corrects clinical diagnosis. AFP Surveillance is of particular importance as well as fecal sampling up to 48 hours, from the onset of paralysis, and follow-up after the 60th day in children <15 years.